MD Anderson and AmMax Bio announced agreements to develop and advance AmMax’s AMB-066 monoclonal antibody therapy for colorectal cancer with minimal residual disease.
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
